PMID- 9347181
OWN - NLM
STAT- MEDLINE
DCOM- 19971205
LR  - 20220318
IS  - 0835-7900 (Print)
IS  - 0835-7900 (Linking)
VI  - 11 Suppl B
DP  - 1997 Sep
TI  - Proton pump inhibitors in acute healing and maintenance of erosive or worse 
      esophagitis: a systematic overview.
PG  - 66B-73B
AB  - The aim of this paper is to present a systematic overview of the efficacy of the 
      proton pump inhibitors (PPI), omeprazole and the newer lansoprazole, in the 
      healing and maintenance of erosive or worse (grade II to IV) esophagitis. At the 
      time of the 1996 gastroesophageal reflux disease (GERD) consensus meeting, a 
      third PPI, pantoprazole, was not yet available in Canada and was, therefore, not 
      discussed. The present review is therefore restricted to patients with more 
      severe disease than that of the average patient who presents to the family 
      physician with symptoms of mild GERD. In these patients with endoscopic evidence 
      of damaged esophageal mucosa, both proton pump inhibitors were highly effective 
      and safe in acute healing of erosive esophagitis and were significantly better 
      than H2 receptor antagonists, healing faster and much more completely, with 
      shorter durations of treatment. Suggested initial doses were omeprazole 20 mg 
      once daily and lansoprazole 30 mg once daily, which were consistent with the 
      manufacturer's recommendations. Once patients with this degree of esophagitis 
      have their mucosal lesions healed, they almost inevitably have recurrence of 
      esophagitis (80% at one year) unless some form of maintenance therapy is 
      continued. Unfortunately, for these patients with healed erosive or ulcerative 
      esophagitis, H2 receptor antagonists appear to be no better than placebo, and a 
      PPI is the only class of drug able to minimize relapse significantly.
FAU - Chiba, N
AU  - Chiba N
AD  - Department of Medicine, McMaster University, Hamilton, Ontario. 
      chiban@fhs.csu.mcmaster.ca
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - Can J Gastroenterol
JT  - Canadian journal of gastroenterology = Journal canadien de gastroenterologie
JID - 8807867
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Esophagitis, Peptic/*drug therapy/pathology
MH  - Histamine H2 Antagonists/therapeutic use
MH  - Humans
MH  - Lansoprazole
MH  - Omeprazole/*analogs & derivatives/*therapeutic use
MH  - *Proton Pump Inhibitors
MH  - Recurrence
RF  - 37
EDAT- 1997/11/05 00:00
MHDA- 1997/11/05 00:01
CRDT- 1997/11/05 00:00
PHST- 1997/11/05 00:00 [pubmed]
PHST- 1997/11/05 00:01 [medline]
PHST- 1997/11/05 00:00 [entrez]
PST - ppublish
SO  - Can J Gastroenterol. 1997 Sep;11 Suppl B:66B-73B.